Advertisement

Topics

AstraZeneca invests $29M in mRNA-based lung drugs

05:07 EDT 24 Aug 2017 | SmartBrief

AstraZeneca is investing $29 million in Germany-based startup Ethris to develop messenger RNA-based drugs for asthma, chronic -More

Original Article: AstraZeneca invests $29M in mRNA-based lung drugs

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca invests $29M in mRNA-based lung drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Asthma
Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...